Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Sells Shares Under 10b5-1 Trading Plan

CEO Samarth Kulkarni sold 18,360 common shares of CRISPR Therapeutics at an average price of $55.205 under a pre-arranged 10b5-1 trading plan.

Summary

• On February 19, 2025, Samarth Kulkarni, CEO of CRISPR Therapeutics, sold 18,360 common shares of the company.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 13, 2024.
• The shares were sold at a weighted average price of $55.205, with individual transactions ranging from $55.02 to $55.46.
• Following the transaction, Kulkarni directly owns 171,613 common shares and indirectly owns 85,622 shares through The Kulkarni 2023 GRAT.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was conducted under a pre-planned trading plan. It doesn't necessarily indicate a positive or negative outlook on the company's future.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 trading plans allows executives to sell shares in a pre-planned manner to avoid accusations of insider trading. Investors often monitor these filings to understand executive sentiment and potential future stock movements.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

CRISPR Therapeutics, Samarth Kulkarni, stock sale, Form 4, 10b5-1 trading plan, executive compensation, insider trading